RecallHawk

JANUMET (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE)

MSD SUB MERCK

Summary

FDA approved JANUMET (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) by MSD SUB MERCK. NDA (New Drug) approval (Labeling) on 2022-06-21. TABLET, ORAL.

Details

Source

Drug Approval

External ID

NDA022044-52

Action Date

2022-06-21

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

JANUMET (generic: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE), TABLET, ORAL. Application: NDA022044

Context & Analysis

MSD SUB MERCK has 7 FDA actions in our database.

Frequently Asked Questions

How often does MSD SUB MERCK have FDA actions?

MSD SUB MERCK has 7 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA022044-52" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions